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Abstract: It is recommended that developers of Point Of Care Tests (POCTs) assess the care pathway
of the patient population of interest in order to understand if the POCT fits within the pathway
and has the potential to improve it. If the variation of the pathway across potential hospitals is
large, then it is likely that the evaluation of effectiveness is harder and the route towards large-scale
takes adoption longer. Evaluating care pathways can be a time-consuming activity when conducted
through clinical audits or interviews with healthcare professionals. We have developed a more
rapid methodology which extrapolates the care pathway from local hospital guidelines and assesses
their variation. Sepsis kills 46,000 people per year in the UK with societal costs of up to £10 billion.
Therefore, there is a clinical need for an optimized pathway. By applying our method in this field,
we were able to assess the variation in current hospital guidelines for sepsis and infer the potential
impact this may have on the evidence development on innovations in this applications. We obtained
15 local sepsis guidelines. Two independent reviewers extracted: use of the national early warning
score (NEWS), signs and risk factors informing the decision to prescribe antibiotics, and the number
of decisional steps up to this point. Considerable variation was observed in all the variables, which is
likely to have an impact on future clinical and economic evaluations and adoption of POCT for the
identification of patients with sepsis.
Keywords: sepsis; diagnosis; guidelines; POCT; evaluation
1. Introduction
It is recommended that developers of Point Of Care Test (POCT) understand the care pathway of
the patient population of interest. The care pathway is the journey of a patient with a specific condition
in the healthcare system [1], and its analysis is useful to evaluate whether the new POCT could fit in
the current pathway and has the potential to improve it [2–4].
Methods to analyze the pathways include review of national guidelines, interviews with
stakeholders (e.g., clinicians, laboratory professionals and patients) and audits. These can be
time-consuming, especially if the aim is to sample many hospitals. We decided to analyze hospital
guidelines as a proxy for the real care pathways.
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Understanding how hospital guidelines are used in practice represents a powerful tool, especially
in complex diseases where the definition of the disease is non-trivial. Indeed, guidelines could serve as
an operational definition of the disease: when in the pathway initiation of treatment is recommended,
then a patient can be considered “diseased”.
When guidelines are not standardized across the country, variations can affect prevalence and,
indirectly, clinical and economic evaluation of the POCT (where prevalence of the disease is an essential
parameter). Also, adoption of new POCT is harder in a fragmented clinical scenario.
We developed a methodology to evaluate variation in local hospital guidelines and we focused on
guidelines for identification of patients with suspected sepsis. This work is relevant to the evaluation
of POCTs intended to fit into the sepsis care pathway, for example those based upon procalcitonin
(PCT) testing.
Sepsis is a syndrome with a complex definition [5]: it is a dysregulated response to infection
that causes system-wide inflammation, which can escalate to multiple organ dysfunction [6]. Because
of this complex definition, which is not an operational definition, it is hard to define its prevalence
and as a consequence the mortality rate fluctuates substantially between 29% as reported in UK [7]
and up to 60% elsewhere [8,9]. It is, therefore, difficult to estimate its clinical and economic impact.
Recent estimates report that sepsis kills at least 46,000 people per year in the UK with potential direct
costs to the UK National Health System as high as £1.1 billion per year, and societal costs of up to £10
billion [10]. Guidelines could help in this clinical context.
Clinical guideline NG51 Sepsis: recognition, diagnosis, and early management was published by
the National Institute for Health and Care Excellence (NICE) in 2016 [11]. This provides national
recommendations for recognition, diagnosis, and management of sepsis in all patient populations
in UK, based on a systematic review of efficacy and cost-effectiveness. It recommends considering
the use of an early warning score for suspected sepsis in acute hospital settings. The National Early
Warning Score (NEWS), the most widely used risk scoring system in the UK, is based on 7 physiological
parameters. NEWS was developed in 2012 [12] and updated to NEWS2 in 2017 [13]. Red Flag Sepsis, a
flow chart which recommends different management based on the likelihood of organ dysfunction [14],
built upon NEWS by combining an easy-to-follow pathway with unambiguous recommendations.
NICE acknowledges that the application of its clinical recommendations is not mandatory, given
that local and individual circumstances must also be taken into consideration. Both NICE and the Royal
College of Emergency Medicine (RCEM), author of three national audits of severe sepsis and septic
shock since 2011/12, recommend that all emergency departments have a sepsis lead and their own
individualized sepsis protocol. The RCEM reports that this is the case in 95% and 96% of departments
respectively [15]. Thus, this seems an appropriate clinical context where the variation between local
guidelines can be assessed.
In this paper, we analyze local guidelines for the identification and risk stratification of adult
patients with suspected sepsis in non-specialist acute hospitals (NHS Trusts) in England. Our aim is to
investigate variation in care pathways and discuss its implications. To our knowledge, this is the first
formal evaluation of its kind in relation to local sepsis guidelines.
2. Materials and Methods
We obtained local sepsis guidelines from non-specialist acute NHS Trusts in England, and
extracted information about the pathway for identification of suspected sepsis. Our scope was to
include guidelines applicable to a general adult population, not those relating only to specific groups
such as pregnant patients or those with suspected neutropenic sepsis.
2.1. Sampling Strategy
We aimed to include a representative sample of 10% of Trusts in England, which we considered to
be achievable based on the resources available, and a good balance between resource and the value of
the exercise. In choosing those to request, we sought to include variation in factors that may influence
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organizational operation, such as geographical location, size, and governance arrangements. Thus,
our sampling strategy was designed to capture variation in practice while minimizing the required
sample size. The choice of Trusts was arbitrary other than varying these factors, and the inclusion of
our own Trust. Table 1 shows characteristics of 15 Trusts selected, which included representation from
all nine regions of England. The sizes of the Trusts, as measured by the number of general and acute
beds [16], ranged from the 25–30th to the 95–100th centiles. The sample included both foundation and
non-foundation Trusts, and both teaching and non-teaching Trusts.
Table 1. Characteristics of the 15 NHS England Trusts whose local sepsis guidelines were requested,
ordered by descending size as measured by the number of general and acute beds as a centile range [16].
# Region of England Size Foundation? Teaching? Reason of Exclusion
1 East Midlands 95–100% No Yes
2 North-East 95–100% Yes Yes
3 South-East 85–90% Yes Yes
4 Yorkshire and the Humber 80–85% Yes Yes
5 London 75–80% Yes Yes
6 London 70–50% No Yes
7 North-West 70–50% Yes Yes
8 South-West 65–70% Yes Yes
9 South-West 60–65% No No
10 North-West 55–60% Yes Yes
11 North-West 45–50% No Yes Discrepancies in guideline
12 North-East 40–45% Yes No Response did not include a sepsis guideline
13 West Midlands 40–45% No No Response did not include a sepsis guideline
14 East of England 35–40% Yes Yes Response did not include a sepsis guidelinefor a general adult population
15 Yorkshire and the Humber 25–30% Yes No
2.2. Acquisition of Guidelines
Guidelines were requested by freedom of information (FOI) requests in August 2018. The Freedom
of Information Act 2000 gives anyone the right to request information from public bodies in the UK,
who should respond within 20 working days [17]. Trusts’ FOI departments were contacted by email
and asked to provide: “A copy of your current or most recent local adult sepsis protocol (i.e., guidance
for staff for identification of suspected sepsis in adults), with publication dates and expiry dates where
available. If such a document does not exist, a response to indicate that this is the case.”
2.3. Data Extraction
Responses were deemed valid for analysis if they included a guideline for the identification of
sepsis in adults. Two independent reviewers (authors AB and EK) read each response and listed all
physiological signs, clinical signs, and risk factors included for identification of suspected sepsis. These
items were consolidated into groupings by our local sepsis lead (author BM) as shown in Appendix A.
Physical signs were grouped into categories which best reflected their position on a NEWS chart. Site of
infection was also divided into the anatomical site or physiological system affected. A data extraction
strategy was agreed and documented as a set of instructions (Appendix B) and data extraction form
(Appendix C). The strategy involved determining for each guideline the use of NEWS, then for each
step in the guideline the included signs and risk factor items up to the recommendation to prescribe
antibiotics. A step was deemed to be a question or criterion (or collection of these considered together),
the outcome of which determined how the patient progressed in the pathway. Data were extracted from
the responses independently by the same reviewers according to these instructions, with discrepancies
resolved by discussion including a third reviewer (author SG) to reach agreement and arrive at a final
set of reference results. This group also selected the pathways that they deemed to be the simplest and
most complex.
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2.4. Validation Exercise
To validate the reproducibility of the reference results, two independent reviewers who were not
involved in the process described above (authors AW and AJ) were provided with the instructions,
item groups, and guidelines to perform data extraction. To evaluate the feasibility of this approach as a
standard methodology, the reviewers recorded the length of time taken for analysis of each guideline.
The data extraction error rates were calculated by dividing the number of errors by the number of
potential errors (considering included and excluded items, inclusion of NEWS, steps numbers, and
classification of steps as contributing to an indication of high risk or lower-risk sepsis).
3. Results
All 15 Trusts responded to the FOI request throughout September and October 2018, with response
times ranging from 3 to 39 working days. Three responses were excluded prior to data extraction: one
Trust (14 in Table 1) did not have a policy covering sepsis in a general adult population (only one
for neutropenic sepsis), another (12 in Table 1) returned an emergency department assessment form
without a sepsis guideline, and a third (13 in Table 1) returned a policy covering the management of
deteriorating adult patients without a sepsis guideline. This left 12 guidelines available for the data
extraction exercise.
The remaining guideline publication dates ranged from 2012 to 2017, with the majority (9/12)
having been published within the two years prior to the analysis. The guidelines ranged in length from
a single page to 16 pages, and had different formats, with information presented variably as prose,
lists, tables, and flow diagrams.
One further guideline (11 in Table 1) was excluded after attempting data extraction because
discrepancies within it prevented step numbers and included items being determined, leaving 11
guidelines for analysis (1–10 and 15 in Table 1). Figure 1 summarizes NEWS scores, physiological
signs, clinical signs, and risk factors included in each guideline for the identification of sepsis. A
more detailed version of this table, showing items included by step number, is given in Appendix D.
Two responses described the use of an electronic screening system, into which clinical information is
entered and an alert triggered if a patient is deemed to be at high risk of having sepsis on the basis of
algorithms (details of which were not included in the responses).
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Figure 1. Reference results: A sum ary of NE S scores, physiological signs, clinical signs, and risk
factors included in each guideline for the identification of sepsis. Trusts are ordered from left to right
by descending number of general and acute beds [16].
3.1. Use of Published Scoring Systems and Pathways
The aggregate NEWS score was incorporated into 7 Trusts’ guidelines, and the use of individual
NEWS scores into 5. The use of NEWS in one guideline was indeterminate due to the statement “Does
your patient have an EWS (Early Warning Score) ≥ 3...”. This is because an individual NEWS score
cannot exceed 3, but a threshold of 3 is not normally applied to aggregate score. The relationship
between EWS and NEWS was also unclear. Three Trusts (guidelines 6, 7, 8 in Figure 1) had adopted the
UK Sepsis Trust template [14], but with slight variations. For example, two Trus s’ guidelin s required
any amber fl to be present o proc ed to the next s ep, whereas he third required two amber flags,
and two Trusts’ guidelines included lactate in a fifth step, but the third did not.
3.2. Physiological Signs and Thresholds
According to the groupings determined by BM (Appendix A), 15 signs and risk factor grouping
items were included in the guidelines for identification of sepsis. The number of items included in each
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guideline for primary identification of high-risk sepsis ranged from 4 to 13 (median 11, interquartile
range 2.5). Mental state changes were included in all guidelines, with respiratory rate, oxygen, blood
pressure, pulse rate, and signs of infection included in all but one. The least common items were
blood/lab results, appearing in 2 guidelines, and organ failure, appearing in 3.
3.3. Pathway Structure
Guidelines contained between 2 and 5 steps (median 4, interquartile range 2.5) up to the
recommendation to prescribe antibiotics. Figure 2 presents flow diagrams, one depicting the sepsis
identification pathway deemed to be the simplest, comprising 2 steps including 11 items (guideline 15
in Figure 1 and Appendix D), and the other showing that deemed to be the most complex, comprising
5 steps including 14 items (guideline 8 in Figure 1 and Appendix D).
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Figure 2. Diagrams depicting two sepsis identification pathways, the simplest (A) comprising two steps
including 11 items (guideline 15 in Figure 1 and Appendix D), and the most co plex (B), comprising
five steps including 14 items (guideline 8 in Figure 1 and Appendix D). Steps shown in bold font relate
to primary identification of high-risk sepsis, and those in non-bold font (those on the right in B) relate
to secondary diagnosis of lower-risk sep is.
3.4. Validation Exercise
The data extraction erro rates, when co i results from guideline-naïve reviewers to the
reference results, were 10% and 13% for raters 1 and 2, respectively. There were 133 errors in total (rater
1 = 56, rater 2 = 77): 35 (15, 20) instances of items in the guidelines being missed, 3 (2, 1) of items being
included that were not in the guideline, 88 (34, 54) cases of step numbers being misinterpreted, 6 (4, 2)
cases of items being allocated to the wrong group (as defined in Appendix A), and 1 (1, 0) instance of a
rater classing a non-NEWS item as included in NEWS. Both raters took a mean of 8 minutes to read
each guideline, with times ranging from 1 to 23 minutes.
4. Discussion
4.1. Variation in Sepsis Guidelines
Substantial variation was observed between local guidelines in the identification of patients with
suspected sepsis. The number of items used to recognize high risk patients varied between 4 and 13
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items out of a possible 15, based on signs and symptoms groupings. Pathways ranged from simple,
containing only 2 steps, to more complex, comprising 5 steps and including risk stratification decisions.
The date of our information request was such that guidelines were unlikely to reflect the NEWS2
update 8 months prior [13], and indeed all guidelines preceded this update. Most of the guidelines we
analyzed did refer to NEWS, but not all, and the seven NEWS parameters were not always included in
those that did not. For example, a very low or high temperature would not feed into the process, as
described in one guideline, of determining sepsis risk. We did not analyze differences arising from the
number of red or amber flags required to proceed in one step within a pathway (one, two, or more), or
the thresholds applied to physiological measurements.
These findings support those published previously using different methodology in this disease
area and others [18–21]. Rhee et al [22] found by asking critical care specialists to classify clinical
vignettes that application of the traditional consensus sepsis definition resulted in large variability.
The same group later reported variation in the time taken for sepsis to be identified, and management
initiated [23]. Even after training to standardize the process, there was low agreement between
clinicians reviewing cases to identify these time points.
4.2. The Potential Impact of Uncertainty in Disease Prevalence on POCT Evaluation and Adoption
To facilitate adoption of a new POCT in the healthcare system, the performance, safety, effectiveness,
cost-effectiveness and affordability of a new test has to be demonstrated compared to the current care
pathway for the patient population of interest [24–27].
POCT performance, safety and effectiveness are evaluated with clinical studies and the starting
point of the design of any clinical study is disease prevalence [28]. Disease prevalence is directly linked
to the concept of disease definition, and an operational definition of the disease can be linked to when
a patient is defined as “diseased”, i.e., in need of treatment, in the guidelines. If guidelines across
hospitals are very variable, the disease definition is not clear, and its prevalence will vary across the
country. This has been observed previously in sepsis [10].
Prevalence is an essential consideration during the planning of clinical studies to decide the
sample size needed to observe (or not observe) the outcome of interest with reasonable certainty [29].
Using an inaccurate or wide-ranging prevalence may result in the failure of the study, or in outcome
measures that are too imprecise to be useful. These difficulties have been acknowledged previously in
the context of sepsis [30]. The implication is that evaluations of new POCTs in this clinical context may
be delayed because of a lack of a shared operational definition of the disease, reflected in the variability
of local guidelines.
Diagnostic test accuracy refers to the ability of a test to discriminate between those who have and
those who do not have the target condition. Certain measures of diagnostic accuracy are intrinsically
linked to disease prevalence, including the positive and negative predictive values (PPV and NPV).
These are the probabilities that a patient who tests positive has the disease, or one who tests negative
does not have the disease, respectively. More recently it has also been shown that sensitivity (the
proportion of patients with the target condition who have a positive test result) and specificity (the
proportion of those without the target condition who have a negative test result) are likely to depend
on prevalence if these measures are evaluated in different clinical settings, e.g., emergency departments
versus intensive care units [28]. Without a robust assessment of prevalence, the performance of the test
(its clinical validity) cannot be evaluated with precision.
To assess cost-effectiveness and affordability economic evaluations are used [31,32]. Economic
evaluations consist of a “map” of processes (e.g., disease diagnosed, test results, treatment) and
outcomes (e.g., death or survival) and the probabilities that those processes and outcomes occur in the
population of interest (e.g., prevalence, sensitivity, and specificity of the test, mortality rate). We have
already discussed that sensitivity and specificity may depend on prevalence. Probabilities are essential
parameters in an economic evaluation. A large uncertainty surrounding these essential probabilities
makes the analysis less helpful and more difficult to interpret. This is a common problem, even when
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combining multiple tools to predict economic factors, as shown by Quercioli et al [33], who developed
a composite measure of health to predict expenditure.
Finally, from a practical perspective, if only one (or a small number of) care pathway(s) needed to
be modified on a national scale, as opposed to a large number of local pathways, a new POCT could be
implemented more quickly and at less expense.
4.3. The Potential Impact of Variable Care Pathways in POCT Evaluation and Adoption
As mentioned in the previous section, economic evaluations are based on a model structure that
maps processes and outcomes. This structure is built on the care pathway because it is an overall
representation of the clinical decisions of patients, nurses and doctors [1,32]. If the point in the pathway
where the test might fit is different across hospitals because their care pathways differ, then the structure
of the economic model will need to be adapted (e.g., with sensitivity analysis [32]) or a more high level
structure may be used. This could be particularly problematic in the assessment of affordability. This
analysis is relied upon by budget holders when deciding whether to implement a new technology in
their region/hospital. High variability in the care pathways increases the complexity of the economic
analysis for the evaluation of the POCT during the earlier stages of the evidence generation, but also at
the point of widespread adoption when affordability needs to be demonstrated to the budget holders.
The care pathway also informs the protocol of clinical studies: the point in the pathway where
the test might fit defines the patient population of interest and the series of decisions in the pathway
defines the study processes. A protocol based on one pathway when there is large variability across
the country is unlikely to be generalizable or transferable to other settings.
Outcomes (that often represent patient health) are essential in economic evaluations but are also
the endpoints of clinical studies. Outcomes are also affected by variation in the pathways. In our
sepsis case study, for example, varying pathways could mean a difference in the group of patients
treated with antibiotics for suspected sepsis within each organization. With each step in a pathway,
patients not fulfilling the criteria are diverted, and so Trusts with longer pathways, by, for example
including more signs and symptoms, are likely to treat fewer patients. In addition, the number of steps
and items to consider when deciding whether to prescribe antibiotics may influence the timeliness
of any intervention. Thus, variations in guidelines may affect patient outcomes [20,34]. This is likely
to have contributed to the finding by Churpek et al [35] that different definitions of sepsis lead to
variation in mortality rate. Conversely, oversimplified pathways may result in low specificity and the
well-acknowledged harms of overprescription of antibiotics.
4.4. Strength and Weaknesses of the Methodology
To our knowledge, this analysis is the first of its kind, irrespective of medical specialty. Our
approach uses readily available resources and avoids biases inherent in practitioner surveys [36], and
those due to patient selection in clinical studies. However, the analysis does not capture differences
between guidance and actual practice, or provide insight into how guidelines were developed and
thus the reasons for variation [36]. FOI requests are an efficient way of obtaining information from
public authorities, but the process after a request reaches the FOI contact is hidden, so the source of the
information within the organization is unknown. The burden of the request to the organization should
be weighed up with the benefits of the research. If all guidelines were made publicly available online
(as some, including our own Trusts, are), assessment of variation in local pathways would be more
easily achieved, increasing transparency of care.
Our data extraction methodology, involving two independent reviewers, aligns with that of
systematic literature reviews [37]. Our validation exercise demonstrated error rates lower than the
majority reported in a recent review [38]. This novel approach therefore may be robust. We did not
aim to appraise guideline quality or the development process as existing instruments [36,39] were
not suitable.
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A study by Drennan et al [40], in which 98 local continence policies were obtained from the public
domain and written requests to 38 sites, had methodological similarities with our work. Their study
included a much larger sample than ours, but little information was given about their data extraction
and analysis methodology. Rather, the methods section cited theoretical qualitative frameworks.
The same is true of another study all eight national policy documents and guidelines on palliative
sedation [41]. In addition, neither paper described the data extraction or analysis being carried out by
two or more independent reviewers, as we did.
We devised a strategy to minimize bias in sampling Trusts, while considering factors that may
affect the way in which Trusts operate, including a similar number of sites to that represented in several
recently published, high-profile trials [42–44]. We demonstrated considerable variation based on a
selected 10% of Trusts.
Responses from four of the five Trusts with the fewest beds were excluded; one because of
discrepancies within the guideline and the others because a guideline matching the request was
not received. Therefore only 12 of 15 Trusts (80%) had a local sepsis guideline, compared to 96%
recently reported by the RCEM [15]. This may suggest that smaller Trusts are less likely to have a
(comprehensive) local sepsis guideline for the general population. Unfortunately, this means that
smaller organizations are poorly represented in our results. However, we do not believe that better
representation of small Trusts would alter our conclusion that there is large variation across sepsis
guidelines, which is likely to correlate with large variation in clinical practice. Indeed, the lack of a
guideline is likely to cause variation in clinical practice even within, as well as between, Trusts.
5. Conclusions
We have proposed a novel methodology for analyzing variation in local clinical guidelines, and
using this we found large variation in the identification of patients with suspected sepsis across
UK hospitals.
We advise POCT developers to analyze and visualize the care pathway of patient groups that are
likely to benefit from their technology at the early stages of development (using standard methods,
such as interviews, or the methodology proposed in this article). This would allow them to understand
if their technology has the potential for integration into the current pathway and to be useful to patients,
clinicians, and/or laboratory technicians. As we have shown in this discussion, a possible barrier
to adoption of a new technology is the variability of the care pathways. It is useful to identify this
issue in the early stages of POCT evaluations so that it can be taken into account when planning and
conducting economic and clinical studies, and the route to widespread adoption.
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Appendix A
Table A1. Signs and risk factors groupings.
RESPIRATORY RATE Respiration rate (part of NEWS)Shortness of breath/abnormal breath sounds/breathing hard
OXYGEN
Peripheral capillary oxygen saturation (SpO2) (part of NEWS)
Air or oxygen? (part of NEWS)
New need for oxygen to maintain saturation
Oxygen flow rate/concentration (when on O2)
Oxygen saturation (SaO2)
BLOOD PRESSURE
Systolic blood pressure (part of NEWS)
Mean arterial pressure
Hypotension
PULSE RATE Pulse/heart rate (part of NEWS)
MENTAL STATE CHANGES
Level of consciousness or new confusion (part of NEWS)
New altered mental state
Altered mental state/functional decline
Confusion
New onset confusion
TEMPERATURE
Temperature (part of NEWS)
Fever/hypothermia/chills
Rigors
URINE OUTPUT Urine output
LACTATE Lactate
SKIN CHANGES
Mottled/ashen/cyanosis of skin/lips/tongue
Non-blanching rash
Purpuric rash
LOOKS SICK/CONCERN
Looks sick
Acute unwellness/deterioration
Clinical concern
Relatives concerned
Unwell (fever/chills/confusion)
Non-specific deterioration
ORGAN FAILURE
Acute kidney injury
Potentially life-threatening organ dysfunction
Respiratory failure
Circulatory failure
Central nervous system depression
Kidney/gut/liver failure
Other evidence of organ failure
BLOODS/LABS
Altered white blood cell/c-reactive protein count
Glucose
White cell count
Lab evidence of organ dysfunction
Positive microbiology
White blood cells in cerebral spinal fluid
Blood sugar
RISK FACTORS FOR SEPSIS
Immunosuppression
Recent trauma/surgery
Pregnancy/recent delivery
Intravenous drug misuse
Recent chemotherapy
Recent bone marrow/stem cell transplant
Neutropaenia/neutrophil count
Lines
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Table A1. Cont.
SIGNS OF INFECTION
Possible/suspected/known infection
Myalgia
Severe malaise
New arrhythmia/dysrhythmia
Vomiting/diarrhoea
Abdominal pain/distention
Purulent sputum
Chest X-ray changes
Abscess
Fluid collections
SITE OF INFECTION
Sign of infection at wound or surgery site
Indwelling catheter
Pneumonia/respiratory tract infection
Intraperitoneal infection
Bone/joint infection
Endocarditis
Foreign body/implant infection
Skin/soft tissue infection
Urinary tract infection
Biliary tract infection
Ear-nose-throat/maxillofacial infection
Central nervous system infection
Intravascular catheter infection
Female reproductive system infection
Infection of unknown/other source
Pain passing/foul-smelling urine
Redness/rash/swelling/cellulitis
Meningism
Cellulitis/septic arthritis/infected wound/fasciitis
Device-related infection
Meningitis
Abdominal/bowel perforation
Peritonitis
Endocarditis
Catheter infection
Appendix B
Data extraction instructions.
Instructions
Follow these steps for each guideline. An example is given overleaf.
1. Print the guidelines pack.
2. Keep a record of the amount of time spent extracting data from each guideline.
3. Read through each document, including all prose, lists, tables, and flow diagrams.
4. Complete the Aggregate NEWS and Individual NEWS rows in the data entry table with a tick or
cross to indicate whether aggregate and individual NEWS scores are included inform the decision
to administer antibiotics for suspected sepsis.
5. For each step, determine which sign/symptom/risk factor items are included in that step, and
place the step number against those items in the data entry table. Don’t include items that don’t
inform the decision to administer antibiotics for suspected sepsis
6. Indicate your interpretation of the step numbers on the printed guideline.
7. If the item is included only via reference to NEWS, and not explicitly, include “N” after the step
number in the data entry table.
8. Items separated by “or” or “and/or” should be considered as the same step, those separated by
“and” should be considered as separate steps.
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9. If the current step represents an alternative, lower-risk pathway, and sepsis could have been
diagnosed by an earlier step, place the step number in brackets in the data entry table.
10. Items may appear in more than one step, hence multiple columns are provided for each item.
11. Items may even appear in the same step more than once, both via reference to NEWS and
explicitly. In that case, add both the step number, and the step number with “N” (see overleaf for
an example).
12. Refer to the groupings table to determine which group each item falls into. Every item from the
guidelines should be covered in the groupings table.
13. Data extraction should stop when sepsis has been diagnosed, indicated by the instruction that
antibiotics should be given. The pathway may branch into higher and lower-risk pathways before
that point, and all pathways should be documented (see step 9 above).
14. Record any comments for each Trust in the final row.
15. If discrepancies exist that prevent step numbers from being determined, indicate the items that
are present with a tick rather than step numbers. If discrepancies exist that prevent included
items being determined, the guideline should be excluded.
Example
The completed inclusion table below represents the following information from a sepsis guideline:
• Aggregate NEWS score is included in the pathway, but individual NEWS scores are not.
• Respiratory rate, oxygen, blood pressure, and pulse rate are mentioned explicitly in step 1.
• These items are also included in step 1 via reference to (aggregate) NEWS.
• Mental state changes and temperature are not mentioned explicitly but are included via reference
to (aggregate) NEWS in step 1.
• Signs of infection is included in step 2.
• Mental state changes, respiratory rate, and blood pressure are included in step 3, after which
antibiotics may be administered.
• Step 4, which represents a lower-risk pathway, includes urine output and lactate, after which
antibiotics may be administered.
• The remaining items (skin changes, looks sick/concern, organ failure, bloods/labs, risk factors
for sepsis, and site of infection) are not included in the guideline up to the point(s) of
antibiotic administration.
Table A2. Inclusion table with information from a sepsis guideline.
INCLUSION TABLE X. Trust Name
Aggregate NEWS 3
Individual NEWS 8
Respiratory rate 1 1N 3
Oxygen 1 1N
Blood pressure 1 1N 3
Pulse rate 1 1N
Mental state changes 1N 3
Temperature 1N
Urine output (4)
Lactate (4)
Skin changes
Looks sick/concern
Organ failure
Bloods/labs
Risk factors for sepsis
Signs of infection 2
Site of infection
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Appendix C
Table A3. Data extraction form (Trusts 1–5).
INCLUSION TABLES Trust 1 Trust 2 Trust 3 Trust 4 Trust 5
Aggregate NEWS
Individual NEWS
Respiratory rate
Oxygen
Blood pressure
Pulse rate
Mental state changes
Temperature
Urine output
Lactate
Skin changes
Looks sick/concern
Organ failure
Bloods/labs
Risk factors for sepsis
Signs of infection
Pain score
Site of infection
Comments
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Appendix D
Table A4. Items included in each guideline by step (Trusts 1–5).
INCLUSION TABLES 1 2 3 4 5
Aggregate NEWS ? 3 8 3 3
Individual NEWS ? 8 8 3 8
Respiratory rate 1N 3 1 1N 2 (3) 2N 4 1 2N
Oxygen 1N 3 1 1N 2 (3) 2N 2N
Blood pressure 1N 3 1 1N 2 (3) 2N 4 2N
Pulse rate 1N 3 1 1N 2 (3) 2N 2N
Mental state changes 1N 3 1 1N 2 (3) 2N 4 2N
Temperature 1N 1N (3) 2N 3 1 2N
Urine output 3 2
Lactate 3 1 2 (5)
Skin changes 3 1 2 (5)
Looks sick/concern 1 1 2 2
Organ failure 3 2 (5) 2
Bloods/labs 1
Risk factors for sepsis 1 2 (3) (5)
Signs of infection 2 2 1 (3) 1 3 1
Site of infection (3) 3 1
Key
Trust characteristics:
F Foundation Trust
T Teaching Trust
NEWS scores:
3 Aggregate/individual NEWS score included
8 Aggregate/individual NEWS score not included
? Unclear whether aggregate/individual NEWS score included
Individual items:
e.g., 1 Item included explicitly for primary diagnosis of high-risk sepsis in step 1
e.g., 2N Item included via reference to NEWS for primary diagnosis of high-risk sepsis in step 2
e.g., (3) Item included explicitly for secondary diagnosis of lower-risk sepsis in step 3
Item not included
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Table A5. Items included in each guideline by step (Trusts 6–15).
INCLUSION TABLE 6 7 8 9 10 15
Aggregate NEWS 3 3 3 3 8 8
Individual NEWS 3 3 3 3 8 8
Respiratory rate 1N 3 (4) 1N 3 (4) 1N 3 (4) 1N 2 (4) 1
Oxygen 1N 3 1N 3 1N 3 1N 1
Blood pressure 1N 3 (4) 1N 3 (4) 1N 3 (4) 1N 4 1
Pulse rate 1N 3 (4) 1N 3 (4) 1N 3 (4) 1N 2 (4) 1
Mental state changes 1N 3 (4) 1 1N 3 (4) 1N 3 (4) 1N 2 4 1 1
Temperature 1N (4) 1N (4) 1N (4) 1N 2 1 (4)
Urine output 3 (4) 3 (4) 3 (4) 4 1
Lactate 3 (5) 3 3 (5) 4 1
Skin changes 3 3 3 1
Looks sick/concern 1 (4) 1 (4) 1 (4) 1
Organ failure (5) (5) (5)
Bloods/labs 2 4 (4)
Risk factors for sepsis 3 (4) 3 (4) 3 (4) 2 3 1
Signs of infection 2 (4) 2 (4) 2 (4) 3 (5) 2
Site of infection 2 2 (4) 2 (4) (5) 2
Key
Trust characteristics:
F Foundation Trust
T Teaching Trust
NEWS scores:
3 Aggregate/individual NEWS score included
8 Aggregate/individual NEWS score not included
? Unclear whether aggregate/individual NEWS score included
Individual items:
e.g., 1 Item included explicitly for primary diagnosis of high-risk sepsis in step 1
e.g., 2N Item included via reference to NEWS for primary diagnosis of high-risk sepsis in step 2
e.g., (3) Item included explicitly for secondary diagnosis of lower-risk sepsis in step 3
Item not included
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